Decibel Therapeutics, which is developing treatments for hearing and balance disorders, announced terms for its initial public offering, as reported in NASDAQ.
The company plans to raise $100 million by offering 5.9 million shares at a price range of $16 to $18.
Decibel's lead gene therapy product candidate, DB-OTO, is being developed to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene.
The company is also advancing DB-ATO, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy, and DB-020, which is for the prevention of cisplatin-induced hearing loss and is currently being evaluated in a Phase Ib trial.
To read more NewsPoints articles, click here.